NHS England Offers ‘Improved’ Orkambi Deal, But Vertex Lukewarm

In an effort to break the three-year logjam in talks over access to Vertex Pharmaceuticals Inc.’s cystic fibrosis drug Orkambi, the National Health Service in England says it has made a “revised and improved” offer to the company.

This would include a two-year managed access deal for both Orkambi (ivacaftor/lumacaftor) and Symkevi (tezacaftor/ivacaftor), as well as a “significant” increase